ADMA Biologics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
ADMA develops plasma-derived human immune globulins and operates an FDA-licensed source-plasma collection center in Georgia. Its lead product candidate, RI-001, is being developed for primary immunodeficiency disease. The report covers the unaudited three months ended March 31, 2012, compared with the three months ended March 31, 2011.
In February 2012, the company completed a reverse merger and a private placement. The financing generated approximately $17.3 million of gross cash proceeds and approximately $15.7 million after transaction-related expenses. Preferred stock was converted into common stock, and certain notes and accrued interest were converted into common stock.
Financial Results and Liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Revenue | $4,400 | $0 | New revenue from plasma sales |
| Total costs and expenses | $1.22 million | $1.59 million | Down 23.2% |
| Loss from operations | $1.21 million | $1.59 million | Improved |
| Net loss | $597,314 | $1.58 million | Improved 62.2% |
| Basic and diluted loss per share | $0.23 | $4.50 | Improved |
| Net cash used in operating activities | $2.00 million | $445,119 | Increased use of cash |
| Net cash provided by financing activities | $16.15 million | $297,646 | Primarily the 2012 financing |
Revenue was generated entirely by the Georgia plasma collection center; the company reported no therapeutic or research-and-development product revenue. The filing does not provide a meaningful consolidated margin because revenue was only $4,400 against substantial operating costs.
Cash and cash equivalents were $14.24 million at March 31, 2012, compared with $87,771 at December 31, 2011. Working capital was $14.82 million. Total liabilities were $1.26 million, including $96,614 of leasehold improvement loan obligations; the related-party notes payable were eliminated through repayment or conversion. The company had an accumulated deficit of $30.41 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $4,400 as plasma-center sales began to contribute.
- Research and development expense declined 66.9% to $81,820, primarily because of lower regulatory, consulting, and salary costs following substantial completion of the Phase II study.
- The prior-year period included a nonrecurring $605,297 loss on the sale of research-and-development plasma inventory; no comparable loss occurred in 2012.
- Plasma-center operating expenses increased 22.5% to $461,493, reflecting increased donor collections after FDA approval of the center in August 2011.
- General and administrative expense increased 89.1% to $674,589, primarily because of merger-related legal and accounting costs, increased compensation, and stock-based compensation.
- Interest expense declined 97.3% to $8,494 following repayment or conversion of outstanding notes.
- The company recorded a $617,615 state income-tax benefit from the sale of New Jersey net operating losses, compared with $320,765 in the prior-year period. The proceeds may be subject to repayment if specified program conditions are not met.
- Shares outstanding increased substantially following the financing, preferred-stock conversion, reverse merger, and related transactions. The filing reported 4,654,303 common shares outstanding as of May 14, 2012.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected existing cash and the net February 2012 financing proceeds to fund operating expenses, research and development, and capital expenditures through the third quarter of 2013, based on its then-current projections.
- Management did not expect FDA approval of RI-001 before the second quarter of 2015, if approval occurs at all. The company therefore expected to require additional capital before the third quarter of 2013.
- The company had no existing commitments for future external funding and stated that additional equity, debt, grants, collaborations, or licensing transactions might be unavailable or available only on unfavorable terms.
- Failure to obtain financing could delay, reduce, or eliminate research programs, clinical trials, and commercialization efforts, and could ultimately force the company to curtail or cease operations.
- RI-001 remained subject to additional clinical trials, FDA review, manufacturing requirements, competition, and commercial-viability risks. The company stated that prior clinical results may not predict future results.
- Management expected general and administrative expenses to increase during the remainder of 2012 because of hiring a chief financial officer and additional personnel.
- Disclosure controls and procedures were not effective at March 31, 2012 because of material weaknesses involving the financial-statement closing process, segregation of duties, and accounting expertise. Management planned remediation measures, including hiring a qualified CFO and strengthening system access and closing procedures.
- Subsequent events included additional stock-option grants and the appointment of Brian Lenz as chief financial officer effective May 1, 2012.
Important Facts for Investors to Verify
- Whether the company can raise the additional capital required before the projected third-quarter 2013 funding runway expires.
- The timing, design, enrollment, cost, and results of the planned Phase III trial for RI-001 and the likelihood and timing of FDA approval.
- Whether plasma-center collections and sales can scale sufficiently to offset operating costs.
- The terms and potential dilution associated with outstanding options, warrants, and any future equity financing.
- Compliance with conditions attached to the New Jersey net operating loss sale and the potential for repayment of related proceeds.
- Progress in remediating the reported material weaknesses in internal control over financial reporting.
- The company’s ongoing cash burn, accumulated deficit, and ability to fund operations after the stated third-quarter 2013 runway.